InvestorsHub Logo
Followers 13
Posts 1020
Boards Moderated 0
Alias Born 07/19/2013

Re: None

Friday, 11/01/2019 10:13:20 AM

Friday, November 01, 2019 10:13:20 AM

Post# of 1856
BioVie Submits Protocol for Phase 2b/3 Refractory Ascites Study to FDA
SANTA MONICA, CA / ACCESSWIRE / October 22, 2019 / BioVie Inc. (BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for liver disease, announced today that it has submitted for assessment by the U.S. Food and Drug Administration ("FDA") the Phase 2b/3 clinical trial protocol for using BIV201 (continuous infusion terlipressin) to treat ascites due to chronic liver cirrhosis in patients who are refractory to or cannot tolerate diuretic therapy.
more...https://finance.yahoo.com/quote/BIVI?p=BIVI

Corporate Presentation | October 2019
https://www.biovieinc.com/wp-content/uploads/2019/10/BioVie-Corp-Presentation_website_Oct-2019.pdf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ARWR News